2929 N COMMERCE PKWY, MIRAMAR, FL
Announces Pricing of $1.5 Million Private Placement
Amendment No. 1 to Preliminary Proxy Statement Filed by HCW Biologics
Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
Financial Statements Restatement - Q1 2026 10-Q Amendment
Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
Other Events
Regained Compliance with Bid Price Rule
Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
Q2
Amended Quarterly Report
Q1
FY 2025
Q3
Notice of Late Filing for Quarterly Report
Notice of Exempt Offering of Securities
S-1
Effectiveness Notice
Amended Registration Statement for Securities
Definitive Proxy Statement
PRER14A
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload